study, a similar direction and magnitude of the rs2036527 effect was observed in those receiving the active bupropion treatment, which was not statistically significant (during treatment OR=0.54 and end of treatment OR=0.59, Fig.2B). Adjusting for age, sex, baseline CPD, and menthol status did not meaningfully alter the magnitude of these odds ratios (during treatment OR=0.56 and end of treatment OR=0.61, Fig.2B) nor did adjusting for CYP2B6 genotype, the main bupropion-metabolizing enzyme (during treatment OR=0.53 and end of treatment OR=0.59).
